文献速递药物不良反应与药物警戒

儿童致死性药物不良反应:WHO药物警戒数据库2010-2019年描述性研究

Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019.
PubMed 文献 · Br J Clin Pharmacol · 2022-08-17

致死性报告多见于男孩、28天至23月龄,主要来自美洲和欧洲,涉及抗感染药物(主要为疫苗)、中枢神经系统药物、抗肿瘤/免疫调节药物和心血管药物,且不同洲际和年龄组间存在较大差异。

要点

  • 儿童致死性药物不良反应约占全部报告的0.13%,男孩及2岁以下儿童报告风险更高。
  • 除抗感染药物(主要为疫苗)外,神经精神类药物是常见涉及药物。
  • 致死性药物不良反应的药物类别分布因洲际和年龄组不同而差异较大。

核心结论

  • 致死性药物不良反应仅占儿童全部注册药物不良反应的很小部分(约1/1000)。
  • 致死性报告在男孩和生命最初2年内更常见。
  • 除抗感染药物(疫苗)外,神经精神类药物最常涉及,且因洲际和年龄组不同差异较大。

研究设计与样本

  • 描述性研究,基于WHO药物警戒数据库2010-2019年医生报告的儿童(<18岁)致死性结局报告。

主要发现

  • 致死性报告主要发生于男孩,年龄为28天至23个月。
  • 报告主要来自美洲和欧洲,涉及抗感染药物(主要为疫苗)、中枢神经系统药物(维加巴林、对乙酰氨基酚、哌甲酯等)、抗肿瘤/免疫调节药物(主要为沙利度胺)和心血管药物(主要为波生坦),男孩与女孩间无重大差异。
  • 报告风险在男孩、<23月龄儿童、美洲和非洲更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Adverse drug reactions (ADRs) represent a significant public health burden. There are few data on fatal ADRs in children. This population is particularly at risk due to metabolic and physiological immaturity, frequent off-label drug use and limited paediatric clinical pharmacology studies. The study investigated the main characteristics of drug-related deaths registered in World Health Organization pharmacovigilance database, during the past decade. METHODS: Fatal outcomes registered between 2010 and 2019 in children (<18 y) and reported by physicians were investigated. Age, sex and suspected drugs were described and disproportionality analyses investigated differences according to sex, age and continents with calculation of reporting odds ratio and its 95% confidence interval. RESULTS: Among the 1 198 560 reports registered in children, 1585 (0.13%) were fatal. They occurred mainly in boys, aged 28 days-23 months. Reports mostly came from the Americas and Europe and involved, besides anti-infectious drugs (mainly vaccines), central nervous system (vigabatrin, paracetamol, methylphenidate…) and antineoplastic/immunomodulating (mainly thalidomide) and cardiovascular (mainly bosentan) drugs without major differences between boys and girls. Large differences were found according to continents and age. The risk of reporting was higher in boys, in children aged <23 months, in the Americas and Africa. CONCLUSION: Fatal ADRs represented a small part (around 1/1000) of total registered ADRs, occurred more frequently in boys and during the first 2 years of life. Beside anti-infectious drugs (vaccines), neuropsychiatric drugs were the most frequently involved, with large differences according to continents and classes of age.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Montastruc JL. Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019. Br J Clin Pharmacol. 2022. PMID: 35881623. doi:10.1111/bcp.15470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。